FibroBiologics, Inc. is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 270+ United States and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. Its advanced product candidates are CYWC628, CYPS317, CYMS101 and CybroCell. It has completed its IND-enabling pre-clinical studies for the development of CYWC628 as a topically administered allogeneic fibroblast cell-based therapy for wound healing. CYPS317 is its allogeneic intravenously administered fibroblast spheroid cell-based investigational therapeutic for the treatment of psoriasis. It is developing CYMS101 as an intravenously administered allogeneic fibroblast single cell, and fibroblast spheroid, cell-based therapy to treat multiple sclerosis (MS).
Back to dashboard
Company Information
About this company
Key people
Pete O'Heeron
Chairman of the Board, Chief Executive Officer, Founder
Jason D. Davis
Chief Financial Officer
Hamid Khoja
Chief Scientific Officer
Ruben Garcia
General Counsel
Kathleen Rubins
Director
Leigh Steinberg
Director
Richard Cilento
Independent Director
Stacy Coen
Independent Director
Robert E. Hoffman
Independent Director
Click to see more
Key facts
- Shares in issue6.96m
- EPICFBLG
- ISINUS31573L2043
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$10.32m
- Employees15
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.